Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 2
1974 6
1975 39
1976 83
1977 30
1978 60
1979 74
1980 66
1981 101
1982 116
1983 112
1984 144
1985 154
1986 162
1987 162
1988 165
1989 203
1990 209
1991 194
1992 211
1993 281
1994 243
1995 239
1996 233
1997 263
1998 250
1999 280
2000 298
2001 254
2002 223
2003 253
2004 243
2005 284
2006 301
2007 313
2008 356
2009 340
2010 337
2011 338
2012 317
2013 368
2014 396
2015 366
2016 366
2017 373
2018 407
2019 421
2020 304
Text availability
Article attribute
Article type
Publication date

Search Results

10,197 results
Results by year
Filters applied: . Clear all
Page 1
Naltrexone: A Pan-Addiction Treatment?
Aboujaoude E, Salame WO. Aboujaoude E, et al. CNS Drugs. 2016 Aug;30(8):719-33. doi: 10.1007/s40263-016-0373-0. CNS Drugs. 2016. PMID: 27401883 Review.
Despite the very different presentations within and between both addiction categories, the data, as a whole, show consistency in favor of naltrexone's relative efficacy and safety. ...Further, naltrexone's seemingly broad anti-addiction efficacy suppor …
Despite the very different presentations within and between both addiction categories, the data, as a whole, show consistency in favor of …
Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy.
Harrison TK, Kornfeld H, Aggarwal AK, Lembke A. Harrison TK, et al. Anesthesiol Clin. 2018 Sep;36(3):345-359. doi: 10.1016/j.anclin.2018.04.002. Epub 2018 Jul 11. Anesthesiol Clin. 2018. PMID: 30092933 Review.
As part of a national effort to combat the current US opioid epidemic, use of currently Food and Drug Administration-approved drugs for the treatment of opioid use disorder/opioid addiction (buprenorphine, methadone, and naltrexone) is on the rise. ...This article reviews …
As part of a national effort to combat the current US opioid epidemic, use of currently Food and Drug Administration-approved drugs for the …
Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies.
Hendershot CS, Wardell JD, Samokhvalov AV, Rehm J. Hendershot CS, et al. Addict Biol. 2017 Nov;22(6):1515-1527. doi: 10.1111/adb.12425. Epub 2016 Jul 14. Addict Biol. 2017. PMID: 27411969 Free PMC article.
This meta-analysis aimed to quantify naltrexone's effects on alcohol self-administration and craving in the context of placebo-controlled human laboratory trials. ...From a clinical perspective, these results may provide additional evidence regarding naltrexone
This meta-analysis aimed to quantify naltrexone's effects on alcohol self-administration and craving in the context of placebo …
Explaining Naltrexone's Interference With Ketamine's Antidepressant Effect.
Wang M, Kaplin A. Wang M, et al. Am J Psychiatry. 2019 May 1;176(5):410-411. doi: 10.1176/appi.ajp.2019.19010044. Am J Psychiatry. 2019. PMID: 31039639 No abstract available.
Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).
Malone M, McDonald R, Vittitow A, Chen J, Obi R, Schatz D, Tofighi B, Garment A, Kermack A, Goldfeld K, Gold H, Laska E, Rotrosen J, Lee JD. Malone M, et al. Contemp Clin Trials. 2019 Jun;81:102-109. doi: 10.1016/j.cct.2019.04.006. Epub 2019 Apr 12. Contemp Clin Trials. 2019. PMID: 30986535 Free PMC article. Clinical Trial.
BACKGROUND: Extended-release naltrexone (XR-NTX, Vivitrol®) and daily oral naltrexone tablets (O-NTX) are FDA-approved mu opioid receptor antagonist medications for alcohol dependence treatment. ...This study will estimate XR-NTX's treatment and cost effectiv …
BACKGROUND: Extended-release naltrexone (XR-NTX, Vivitrol®) and daily oral naltrexone tablets (O-NTX) are FDA-approved mu opio …
Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy.
Mann K, Torup L, Sørensen P, Gual A, Swift R, Walker B, van den Brink W. Mann K, et al. Eur Neuropsychopharmacol. 2016 Dec;26(12):1941-1949. doi: 10.1016/j.euroneuro.2016.10.008. Epub 2016 Nov 12. Eur Neuropsychopharmacol. 2016. PMID: 27842940 Review.
Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report.
Muller G, Grieshaber R, Talley JF, Riepl M, Fellows D. Muller G, et al. Int J Pharm Compd. 2018 Jul-Aug;22(4):270-278. Int J Pharm Compd. 2018. PMID: 30021181
In this article, we describe the successful use of a compounded formulation of oral low-dose naltrexone to manage guttate psoriasis in a 75-year-old white male patient. That therapy produced only 1 adverse effect (dry skin near the lesions on the patient's arms and …
In this article, we describe the successful use of a compounded formulation of oral low-dose naltrexone to manage guttate psoriasis i …
Low-dose Naltrexone Therapy for Psoriasis.
Weinstock LB, Cottel J, Aldridge L, Egeberg A. Weinstock LB, et al. Int J Pharm Compd. 2020 Mar-Apr;24(2):94-96. Int J Pharm Compd. 2020. PMID: 32196470
Two recent case reports suggested that low-dose naltrexone is effective. Cases from our practice are presented in order to further the evidence of efficacy and safety of low-dose naltrexone in the treatment of psoriasis. ...Low-dose naltrexone regulates lymph …
Two recent case reports suggested that low-dose naltrexone is effective. Cases from our practice are presented in order to further th …
[Naltrexone].
Schifano F, Murri R, Gava R. Schifano F, et al. G Clin Med. 1989 May;70(5):379-84. G Clin Med. 1989. PMID: 2666229 Review. Italian. No abstract available.
Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis.
Palpacuer C, Hammas K, Duprez R, Laviolle B, Ioannidis JPA, Naudet F. Palpacuer C, et al. BMC Med. 2019 Sep 16;17(1):174. doi: 10.1186/s12916-019-1409-3. BMC Med. 2019. PMID: 31526369 Free PMC article.
The primary outcome was the vibration of effects (VoE), i.e. the range of different results of the indirect comparison between nalmefene and naltrexone. ...The standardized effect size was negative at the 1st percentile (- 0.29, favouring nalmefene) and positive at the 99t …
The primary outcome was the vibration of effects (VoE), i.e. the range of different results of the indirect comparison between nalmefene and …
10,197 results
Jump to page
Feedback